Physician profile
Ana Ross
NPI 1447220074
$417,462.31
in general payments reported to CMS, 2019-2025
42 companies · $78K in 2025
The $78K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $46K · 2021: $53K · 2022: $52K · 2023: $55K · 2024: $45K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $41K · Food and Beverage: $17K · Travel and Lodging: $15K · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,725.00 |
| Consulting Fee | $40,934.50 |
| Food and Beverage | $17,306.80 |
| Travel and Lodging | $15,172.08 |
| Education | $284.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112,236.15 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $56,580.66 | 2019-2025 | |
| Lilly USA, LLC | $54,882.82 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Genzyme Corporation | $46,363.76 | 2019-2025 | |
| Amgen INC. | $41,546.09 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $27,806.22 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $25,307.37 | 2019-2025 | Cosentyx |
| Janssen Biotech, INC. | $11,366.56 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $9,716.12 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $7,162.78 | 2019-2025 | Orencia, Sotyktu |
| Gilead Sciences, INC. | $6,569.64 | 2019-2020 | |
| Pfizer International LLC | $4,500.00 | 2021 | |
| Sobi, INC | $2,953.54 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,709.91 | 2019-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $2,310.66 | 2019-2023 | Krystexxa |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $1,014.25 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $843.85 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $481.72 | 2019-2025 | Actemra, Gazyva |
| Organon LLC | $463.85 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Alexion Pharmaceuticals, INC. | $347.86 | 2019-2025 | Strensiq |
| Janssen Scientific Affairs, LLC | $296.04 | 2019-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $273.86 | 2020-2023 | Acthar |
| Aurinia Pharma U.S., INC. | $236.78 | 2022-2024 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $205.51 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $201.46 | 2023-2024 | Idacio, Tyenne |
| Sanofi-Aventis U.S. LLC | $184.67 | 2021-2024 | |
| Boston Scientific Corporation | $167.95 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Medexus Pharma, INC. | $111.06 | 2019 | |
| Sandoz INC. | $103.61 | 2024-2025 | Hyrimoz, Jubbonti |
| Celgene Corporation | $94.07 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $67.21 | 2024 | Arcalyst |
| Almatica Pharma LLC | $61.43 | 2025 | Teriparatide |
| Eli Lilly and Company | $47.87 | 2024 | Taltz |
| Ani Pharmaceuticals, INC. | $42.13 | 2025 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $40.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.02 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $27.27 | 2019 | |
| Scilex Pharmaceuticals INC. | $22.67 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.73 | 2023 | Opsumit |
| Invivyd INC | $20.16 | 2025 | Pemgarda |
| Tersera Therapeutics LLC | $18.96 | 2025 | Quzyttir |
| Depuy Synthes Sales INC. | $14.12 | 2025 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.